Senate Report: Drugmakers Spent Millions Pushing Opioids in Patient Groups

  • 0

Senate Report: Drugmakers Spent Millions Pushing Opioids in Patient Groups

The report dives into the connections between corporate donations and the advancement of opioids-friendly messaging.

By Katelyn Newman , Digital Producer, Staff Writer |Feb. 13, 2018, at 11:03 a.m.

Senate Report: Drugmakers Spent Millions Pushing Opioids in Patient Groups

Drugmakers have given more than $10 million to patient advocacy groups and affiliated physicians since 2012 to promote opioid use to individuals seeking help for chronic pain management, according to a report released by a U.S. Senator Monday.

Published by Sen. Claire McCaskill, D-Mo., the 23-page report looked into the financial connections between five pharmaceutical companies – Purdue Pharma L.P., Janssen Pharmaceuticals, Inc., Mylan N.V., Depomed, Inc. and Insys Therapeutics, Inc. – and 14 patient advocacy groups “working on chronic pain and other opioid-related issues” between 2012 and 2017.

“These groups have issued guidelines and policies minimizing the risk of opioid addiction and promoting opioids for chronic pain, lobbied to change laws directed at curbing opioid use, and argued against accountability for physicians and industry executives responsible for overprescription and misbranding,” the report states.

“Notably, a majority of these groups also strongly criticized 2016 guidelines from the Centers for Disease Control and Prevention that recommended limits on opioid prescriptions for chronic pain – the first national standards for prescription opioids and a key federal response to the ongoing epidemic,” it continued.

The connection between medical culture with the pharmaceutical industry’s goals means that many of the groups – with the U.S. Pain Foundation receiving the largest amount of payments – may have significantly contributed to the conditions that have led to the U.S. opioid epidemic, the report concludes.

Facebooktwittergoogle_plusredditpinterestlinkedinmail

Leave a Reply